Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes;Impact de la glycémie postprandiale sur le taux d'HbA1c des patients diabétiques de type 2

Diabetes and Metabolism

Volumn 36, Issue 5, 2010, Pages 389-394

  Schernthaner, G ^a   Guerci, B ^b   Gallwitz, B ^c   Rose, L ^d   Nicolay, C ^e   Kraus, P ^e   Kazda, C ^e  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b INSERM   (France)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Gemeinschaftspraxis   (Germany)

^e LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Beta cell function; Fasting hyperglycaemia; HbA1c; Insulin resistance; Postprandial hyperglycaemia; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 78649449693     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.04.004     Document Type: Article

References (18)

1. Kahn S.E. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:4047-4058.
2. Chen K.W., Boyko E.J., Bergstrom R.W., Leonetti D.L., Newell-Morris L., Wahl P.W., et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM: 5-year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995, 18:747-753.
3. Pimenta W., Korytkowski M., Mitrakou A., Jenssen T., Yki-Jarvinen H., Evron W., et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995, 273:1855-1861.
4. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
5. Pratley R.E., Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001, 44:929-945.
6. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
7. 1c. Diabetes Care 2003, 26:881-885.
8. Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
9. Brodows R.G., Qu Y., Johns D., Kim D., Holcombe J.H. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:1395-1397.
10. Leiter L.A., Ceriello A., Davidson J.A., Hanefeld M., Monnier L., Owens D.R., et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005, 27(Suppl. B):S42-S56.
11. 1c levels. Diabetes Res Clin Pract 2007, 77:280-285.
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
13. Keskin M., Kurtoglu S., Kendirci M., Atabek M.E., Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005, 115:e500-e503.
14. Phillips D.I., Clark P.M., Hales C.N., Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994, 11:286-292.
15. Eklund M., Shaat N., Almgren P., Groop L., Berntorp K. Prediction of postpartum diabetes in women with gestational diabetes mellitus. Diabetologia 2010, 53:452-457.
16. Nathan D.M. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002, 347:1342-1349.
17. Consoli A., Gomis R., Halimi S., Home P.D., Mehnert H., Strojek K., et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004, 30:509-516.
18. Kazda C., Gallwitz B., Simó R., Guzmán J.R., Kraus P., Nicolay C., Rose L., Schernthaner G. The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. Diabetes Obes Metab 2009, 11:1131-1137.